We found a significant decrease in tumor growth rates (Fig. 7a, b), significant lower ascites volumes (Fig. 7c), and significantly higher circulating ITLN1 levels and lower glucose levels in ITLN1-treated mice compared with control mice (Fig. 7d, e). This evidence concerns the gene ITLN1 and neoplasm.